3/26/2013

Large drug firms including Merck, Eli Lilly and Co. and Pfizer urged the FDA to bolster its draft guidance on enrichment measures for clinical trials with more examples involving additional therapeutic areas. Pharmaceutical companies also called for increased guidance involving diagnostics.

Related Summaries